David S Moura, Jose L Mondaza-Hernandez, Paloma Sanchez-Bustos, Maria Peña-Chilet, Juan A Cordero-Varela, Maria Lopez-Alvarez, Jaime Carrillo-Garcia, Marta Martin-Ruiz, Pablo Romero-Gonzalez, Marta Renshaw-Calderon, Rafael Ramos, David Marcilla, Ramiro Alvarez-Alegret, Carolina Agra-Pujol, Francisco Izquierdo, Luis Ortega-Medina, Francisco Martin-Davila, Carmen Nieves Hernandez-Leon, Cleofe Romagosa, Maria Angeles Vaz Salgado, Javier Lavernia, Silvia Bagué, Empar Mayodormo-Aranda, Rosa Alvarez, Claudia Valverde, Javier Martinez-Trufero, Carolina Castilla-Ramirez, Antonio Gutierrez, Joaquin Dopazo, Nadia Hindi, Jesus Garcia-Foncillas, Javier Martin-Broto
HMGA1 is a structural epigenetic chromatin factor that has been associated with tumor progression and drug resistance. Here, we reported the prognostic/predictive value of HMGA1 for trabectedin in advanced soft-tissue sarcoma (STS) and the effect of inhibiting HMGA1 or the mTOR downstream pathway in trabectedin activity. The prognostic/predictive value of HMGA1 expression was assessed in a cohort of 301 STS patients at mRNA (n = 133) and protein level (n = 272), by HTG EdgeSeq transcriptomics and immunohistochemistry, respectively...
May 17, 2024: Cellular and Molecular Life Sciences: CMLS